ecancermedicalscience

Review

Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door

17 Jan 2022
Mauro Daniel Spina Donadio, Dirce Maria Carraro, Giovana Tardin Torrezan, Celso Abdon Lopes de Mello

Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) genes is gaining importance as predictors of fluoropyrimidine-associated toxicity. The recommendation of dose adjustment for chemotherapy guided by the presence of polymorphisms of the DPYD gene can potentially improve treatment safety for a large number of patients, saving lives, avoiding complications and reducing health care costs. This article discusses how personalisation of fluoropyrimidine treatment based on the identification of DPYD variants can mitigate toxicities and be cost effective.

Related Articles

Manas Dubey, Partha Sarathi Roy, Ankur Bhattacharyya, Kakoli Medhi, Rajdeep Bose, Munlima Hazarika, Pompi Daimari Buragohain, Zaveri Mohinta, Anupam Sarma
Joseph Daniels, Letlhogonolo Ernity Mosadi, Andrew Yaw Nyantakyi, Edwina Ayaaba Ayabilah, Judith Naa Odey Tackie, Kofi Adesi Kyei
Astghik Voskanyan, Lusine Harutyunyan, Arusyak Ivanyan, Alisa Movsisyan, Nerses Ghahramanyan, Lusine Sahakyan, Shushan Hovsepyan, Samvel Danielyan, Hayk Grigoryan, Gevorg Tamamyan
Adu Bukola Gift, Michael Joseph Otorkpa, Oluwatobi O. Olayode, Ebubechukwu David Joseph, Ademola Abdulhakeem, Efuetlateh John Paul Nchonganyi, Feziechi Chikelundu Anele, Akolade Akeem Habib, Fodop Samuel Ghislain Junior, Oluwanifemi O. Akintoye, Omoregbee Benjamin
Rima Saad Rassam, Ryan R Lion, Siham Cherkaoui, Laila Hessissen, Ximena Garcia-Quintero, Lama Sayegh Najjar, Dolly Noun, Janane Hanna, Rana Yamout, Shahzadi Resham, Khaled Al Habaiba, Anwar Al-Nassan, Joe El-Khoury, Spandana Rayala, Qutaibah Alotaibi, Nahla Gafer, Giuseppe Troisi, Julia Downing, Suheir Rasul, Sima Jeha, Monnie Abraham, Michael J McNeil